<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786498</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00069705</org_study_id>
    <nct_id>NCT02786498</nct_id>
  </id_info>
  <brief_title>Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing</brief_title>
  <acronym>Vita-Shock</acronym>
  <official_title>A Blinded Exploratory Randomized Controlled Trial to Determine Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to determine the effect of vitamin D3 supplementation on fracture healing at
      3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D supplements are increasingly being recommended to healthy adult fracture patients
      without an osteoporotic injury. Although this is a relatively new practice pattern, the basis
      for this adjunct therapy is grounded in the high hypovitaminosis D prevalence rates (up to
      75%) among healthy adult fracture patients, and the strong biologic rationale for the role of
      vitamin D in fracture healing. Briefly, experimental animal studies have demonstrated that
      the concentration of vitamin D metabolites is higher at a fracture callus compared to the
      uninjured contralateral bone, vitamin D supplementation leads to decreased time to union and
      increased callus vascularity, and increases mechanical bone strength compared to controls.
      While evidence to confirm that vitamin D supplementation improves fracture healing in
      clinical studies does not exist, the pre-clinical data are compelling and worthy of further
      investigation.

      With modern orthopaedic surgical care, rates of complications following tibia and femoral
      shaft fractures can be as high as 15%. Complications, including delayed union, nonunion, or
      infection often require secondary surgical procedures and result in profound personal and
      societal economic costs. While surgeons continue to seek advances in surgical technique, it
      is becoming increasingly obvious that innovations in orthopaedic techniques or implants are
      unlikely to eliminate complications. As a result, considerable attention is currently focused
      on adjunct biologic therapies, such as vitamin D.

      A recent survey of 397 orthopaedic surgeons showed that only 26% routinely prescribe vitamin
      D supplementation to adult fracture patients. Of the 93 surgeons who indicated that they
      routinely prescribe vitamin D supplementation, 29 different dosing regimens were described
      ranging from low daily doses of 400 IU to loading doses of 600,000 IU. This suggests a high
      level of clinical uncertainty surrounding the use and optimal dose of vitamin D
      supplementation in adult fracture patients. If vitamin D supplementation improves fracture
      healing outcomes, then there is a large opportunity to increase its use; however, before
      widespread adoption occurs, research is needed to optimize the dosing strategy, establish the
      dosing safety in the immobilized fracture healing population, and overcome potential
      medication adherence issues among the often marginalized patients that suffer trauma.

      The long-term goal of our research program is to conduct a large phase III RCT to determine
      which dose of vitamin D3 supplementation optimally improves acute fracture healing outcomes
      in healthy adult patients (18-50 years). The current proposed phase II exploratory trial will
      perform important preliminary work to test the central hypothesis that vitamin D3 dose and
      timing of administration is critical for improving fracture healing at 3 months. This trial
      will also inform the feasibility of the large phase III RCT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fracture healing will be assessed clinically using FIX-IT</measure>
    <time_frame>3 months post-injury</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fracture healing will be assessed radiographically using RUST</measure>
    <time_frame>3 months post-injury</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fracture healing will be assessed biochemically using serum levels of the bone turnover marker CTX</measure>
    <time_frame>3 months post-injury</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fracture healing will be assessed biochemically using serum levels of the bone turnover marker PINP</measure>
    <time_frame>3 months post-injury</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum level of 25(OH)D</measure>
    <time_frame>Up to 3 months post-injury</time_frame>
    <description>Correlations will be assessed between participants' 25(OH)D levels at enrolment, changes in 25(OH)D levels from enrolment to 3 months, and 25(OH)D levels at 3 months and fracture healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morisky Medication Adherence Scale (MMAS-8)</measure>
    <time_frame>Up to 3 months post-injury</time_frame>
    <description>Will measure adherence with vitamin D supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient self-report</measure>
    <time_frame>Up to 3 months post-injury</time_frame>
    <description>Will measure adherence with vitamin D supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 12 months post-injury</time_frame>
    <description>Will measure participant safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of calcium</measure>
    <time_frame>Up to 12 months post-injury</time_frame>
    <description>Will measure participant safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of parathyroid hormone</measure>
    <time_frame>Up to 12 months post-injury</time_frame>
    <description>Will measure participant safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants completing bloodwork and imaging outcome measures</measure>
    <time_frame>Up to 12 months post-injury</time_frame>
    <description>Will measure adherence with the protocol</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Fracture</condition>
  <arm_group>
    <arm_group_label>High Loading Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Daily Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Daily Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <arm_group_label>High Loading Dose</arm_group_label>
    <arm_group_label>High Daily Dose</arm_group_label>
    <arm_group_label>Low Daily Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>High Loading Dose</arm_group_label>
    <arm_group_label>High Daily Dose</arm_group_label>
    <arm_group_label>Low Daily Dose</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult men or women ages 18-50 years

          2. Closed or low grade open (Gustilo type I or II) tibial or femoral shaft fracture

          3. Fracture treated with a reamed, locked, intramedullary nail

          4. Acute fracture (enrolled within 7 days of injury)

          5. Provision of informed consent.

        Exclusion Criteria:

          1. Osteoporosis

          2. Stress fractures

          3. Elevated serum calcium (&gt;10.5 mg/dL)

          4. Atypical femur fractures as defined by American Society for Bone and Mineral Research
             (ASBMR) criteria

          5. Pathological fractures secondary to neoplasm or other bone lesion

          6. Patients with known or likely undiagnosed disorders of bone metabolism such as Paget's
             disease, osteomalacia, osteopetrosis, osteogenesis imperfecta etc.

          7. Patients with hyperhomocysteinemia

          8. Patients with an allergy to vitamin D or another contraindication to being prescribed
             vitamin D

          9. Patients currently taking an over the counter multivitamin that contains vitamin D and
             are unable or unwilling to discontinue its use for this study

         10. Patients who will likely have problems, in the judgment of the investigators, with
             maintaining follow-up

         11. Pregnancy

         12. Patients who are incarcerated

         13. Patients who are not expected to survive their injuries

         14. Other lower extremity injuries that prevent bilateral full weight-bearing by 6 weeks
             post-fracture.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Slobogean, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unversity of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheila Sprague, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerard Slobogean, MD</last_name>
    <phone>410-328-6280</phone>
    <email>gslobogean@umoa.umm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yasmin Degani, MPH</last_name>
    <phone>410-706-5917</phone>
    <email>ydegani@umoa.umm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland, R Adams Cowley Shock Trauma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Slobogean, MD</last_name>
      <phone>410-328-6280</phone>
      <email>gslobogean@umoa.umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yasmin Degani, MPH</last_name>
      <phone>410-706-5917</phone>
      <email>ydegani@umoa.umm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert O'Toole, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Nascone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodore Manson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher LeBrun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcus Sciadini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster University, Center for Evidence-Based Orthopaedics</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 8E7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sprague S, Petrisor B, Scott T, Devji T, Phillips M, Spurr H, Bhandari M, Slobogean GP. What Is the Role of Vitamin D Supplementation in Acute Fracture Patients? A Systematic Review and Meta-Analysis of the Prevalence of Hypovitaminosis D and Supplementation Efficacy. J Orthop Trauma. 2016 Feb;30(2):53-63. doi: 10.1097/BOT.0000000000000455. Review.</citation>
    <PMID>26429406</PMID>
  </reference>
  <reference>
    <citation>Omeroğlu S, Erdoğan D, Omeroğlu H. Effects of single high-dose vitamin D3 on fracture healing. An ultrastructural study in healthy guinea pigs. Arch Orthop Trauma Surg. 1997;116(1-2):37-40.</citation>
    <PMID>9006763</PMID>
  </reference>
  <reference>
    <citation>Jingushi S, Iwaki A, Higuchi O, Azuma Y, Ohta T, Shida JI, Izumi T, Ikenoue T, Sugioka Y, Iwamoto Y. Serum 1alpha,25-dihydroxyvitamin D3 accumulates into the fracture callus during rat femoral fracture healing. Endocrinology. 1998 Apr;139(4):1467-73.</citation>
    <PMID>9528922</PMID>
  </reference>
  <reference>
    <citation>Lidor C, Dekel S, Edelstein S. The metabolism of vitamin D3 during fracture healing in chicks. Endocrinology. 1987 Jan;120(1):389-93.</citation>
    <PMID>3023034</PMID>
  </reference>
  <reference>
    <citation>Lidor C, Dekel S, Hallel T, Edelstein S. Levels of active metabolites of vitamin D3 in the callus of fracture repair in chicks. J Bone Joint Surg Br. 1987 Jan;69(1):132-6.</citation>
    <PMID>3029136</PMID>
  </reference>
  <reference>
    <citation>Omeroğlu H, Ateş Y, Akkuş O, Korkusuz F, Biçimoğlu A, Akkaş N. Biomechanical analysis of the effects of single high-dose vitamin D3 on fracture healing in a healthy rabbit model. Arch Orthop Trauma Surg. 1997;116(5):271-4.</citation>
    <PMID>9177802</PMID>
  </reference>
  <reference>
    <citation>Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures Investigators, Bhandari M, Guyatt G, Tornetta P 3rd, Schemitsch EH, Swiontkowski M, Sanders D, Walter SD. Randomized trial of reamed and unreamed intramedullary nailing of tibial shaft fractures. J Bone Joint Surg Am. 2008 Dec;90(12):2567-78. doi: 10.2106/JBJS.G.01694.</citation>
    <PMID>19047701</PMID>
  </reference>
  <reference>
    <citation>Duan X, Al-Qwbani M, Zeng Y, Zhang W, Xiang Z. Intramedullary nailing for tibial shaft fractures in adults. Cochrane Database Syst Rev. 2012 Jan 18;1:CD008241. doi: 10.1002/14651858.CD008241.pub2. Review.</citation>
    <PMID>22258982</PMID>
  </reference>
  <reference>
    <citation>Bhandari M, Guyatt GH, Tong D, Adili A, Shaughnessy SG. Reamed versus nonreamed intramedullary nailing of lower extremity long bone fractures: a systematic overview and meta-analysis. J Orthop Trauma. 2000 Jan;14(1):2-9.</citation>
    <PMID>10630795</PMID>
  </reference>
  <reference>
    <citation>Bonafede M, Espindle D, Bower AG. The direct and indirect costs of long bone fractures in a working age US population. J Med Econ. 2013;16(1):169-78. doi: 10.3111/13696998.2012.737391. Epub 2012 Oct 22.</citation>
    <PMID>23035626</PMID>
  </reference>
  <reference>
    <citation>Antonova E, Le TK, Burge R, Mershon J. Tibia shaft fractures: costly burden of nonunions. BMC Musculoskelet Disord. 2013 Jan 26;14:42. doi: 10.1186/1471-2474-14-42.</citation>
    <PMID>23351958</PMID>
  </reference>
  <reference>
    <citation>Kanakaris NK, Giannoudis PV. The health economics of the treatment of long-bone non-unions. Injury. 2007 May;38 Suppl 2:S77-84. Review. Erratum in: Injury. 2007 Oct;38(10):1224.</citation>
    <PMID>17920421</PMID>
  </reference>
  <reference>
    <citation>Bhandari M, Schemitsch EH. Stimulation of fracture healing: osteobiologics, bone stimulators, and beyond. J Orthop Trauma. 2010 Mar;24 Suppl 1:S1. doi: 10.1097/BOT.0b013e3181d2d683.</citation>
    <PMID>20182228</PMID>
  </reference>
  <reference>
    <citation>Marsell R, Einhorn TA. Emerging bone healing therapies. J Orthop Trauma. 2010 Mar;24 Suppl 1:S4-8. doi: 10.1097/BOT.0b013e3181ca3fab.</citation>
    <PMID>20182234</PMID>
  </reference>
  <reference>
    <citation>Schoelles K, Snyder D, Kaczmarek J, Kuserk E, Erinoff E, Turkelson C, Coates V. The Role of Bone Growth Stimulating Devices and Orthobiologics in Healing Nonunion Fractures [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Sep 21. Available from http://www.ncbi.nlm.nih.gov/books/NBK285118/</citation>
    <PMID>25879121</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Gerard Slobogean</investigator_full_name>
    <investigator_title>Associate Professor of Orthopaedics</investigator_title>
  </responsible_party>
  <keyword>Tibial Shaft</keyword>
  <keyword>Tibia</keyword>
  <keyword>Femoral Shaft</keyword>
  <keyword>Femur</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Fracture Healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

